$ZNTL News

Zentalis Pharmaceuticals To Reveal Its Phase 1b MUIR Trial Data Showing Clinical Activity And Manageable Safety Profile of Azenosertib Plus Paclitaxel In Platinum-Resistant Ovarian Cancer At ASCO 2026; Activity Of The Combined Regimen Across All Dose Cohorts Achieved 39% ORR And 7.3-Month Median PFS;

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Q1 2026 EPS Matches Estimates, Stock Flat

Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress

Zentalis Pharma Q1 EPS $(0.50) Misses $(0.47) Estimate

Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

Zentalis Pharmaceuticals Doses First Patient In Phase 3 ASPENOVA Clinical Trial

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer

Zentalis' Data From Part 1 Of MUIR Trial Focusing On Azenosertib In Combination With Paclitaxel In Platinum-Resistant Ovarian Cancer Accepted For Presentation At ASCO 2026

Zentalis' Data From Part 1 Of MUIR Trial Focusing On Azenosertib In Combination With Paclitaxel In Platinum-Resistant Ovarian Cancer Accepted For Presentation At ASCO 2026

Zentalis (ZNTL) Locks In Its Cancer Drug Dose; Jefferies Raises the Target

Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026

Zentalis Pharmaceuticals Announces Data Presented From Two Posters Regarding Preclinical Activity Of Azenosertib In Triple-Negative Breast Cancer At 2026 American Association For Cancer Research

A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Dose Selection Milestone

What's Behind The Surge In Zentalis Stock?

Zentalis Pharmaceuticals shares are trading higher after Guggenheim raised its price target on the stock from $6 to $10.

Guggenheim Maintains Buy on Zentalis Pharmaceuticals, Raises Price Target to $10

Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

Zentalis Pharmaceuticals shares are trading higher after the company announced it has selected 400mg as the optimal dose of azenosertib in participants with Cyclin E1-positive platinum-resistant ovarian cancer.